ID   CP26B_HUMAN             Reviewed;         512 AA.
AC   Q9NR63; B2R8M7; B7Z2K6; B7Z2P4; B7Z3B8; E4W5W7; Q32MC0; Q53TW1; Q9NP41;
DT   23-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   28-JUN-2023, entry version 182.
DE   RecName: Full=Cytochrome P450 26B1;
DE            EC=1.14.13.- {ECO:0000269|PubMed:10823918, ECO:0000269|PubMed:22020119, ECO:0000269|PubMed:26937021};
DE   AltName: Full=Cytochrome P450 26A2;
DE   AltName: Full=Cytochrome P450 retinoic acid-inactivating 2;
DE            Short=Cytochrome P450RAI-2;
DE   AltName: Full=Retinoic acid-metabolizing cytochrome;
GN   Name=CYP26B1; Synonyms=CYP26A2, P450RAI2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   TISSUE SPECIFICITY, AND INDUCTION.
RC   TISSUE=Retina;
RX   PubMed=10823918; DOI=10.1073/pnas.120161397;
RA   White J.A., Ramshaw H., Taimi M., Stangle W., Zhang A., Everingham S.,
RA   Creighton S., Tam S.-P., Jones G., Petkovich M.;
RT   "Identification of the human cytochrome P450, P450RAI-2, which is
RT   predominantly expressed in the adult cerebellum and is responsible for all-
RT   trans-retinoic acid metabolism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:6403-6408(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT SER-264.
RC   TISSUE=Vascular smooth muscle;
RA   Savenstrand H., Kumawat A., Karlsson M., Eriksson L.A., Sirsjo A.,
RA   Strid A.;
RT   "A spliced version of the human cytochrome P450 26B1 has an alternative
RT   function in retinoic acid metabolism.";
RL   Submitted (NOV-2008) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND VARIANT
RP   SER-264.
RC   TISSUE=Brain, Cerebellum, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-181; VAL-185; HIS-191;
RP   ASN-227; SER-264; LYS-380; GLY-420; CYS-473 AND ILE-479.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, AND VARIANTS RHFCA PRO-146 AND LEU-363.
RX   PubMed=22019272; DOI=10.1016/j.ajhg.2011.09.015;
RA   Laue K., Pogoda H.M., Daniel P.B., van Haeringen A., Alanay Y.,
RA   von Ameln S., Rachwalski M., Morgan T., Gray M.J., Breuning M.H.,
RA   Sawyer G.M., Sutherland-Smith A.J., Nikkels P.G., Kubisch C., Bloch W.,
RA   Wollnik B., Hammerschmidt M., Robertson S.P.;
RT   "Craniosynostosis and multiple skeletal anomalies in humans and zebrafish
RT   result from a defect in the localized degradation of retinoic acid.";
RL   Am. J. Hum. Genet. 89:595-606(2011).
RN   [8]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=22020119; DOI=10.1016/j.bcp.2011.10.007;
RA   Topletz A.R., Thatcher J.E., Zelter A., Lutz J.D., Tay S., Nelson W.L.,
RA   Isoherranen N.;
RT   "Comparison of the function and expression of CYP26A1 and CYP26B1, the two
RT   retinoic acid hydroxylases.";
RL   Biochem. Pharmacol. 83:149-163(2012).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND VARIANT
RP   ARG-64.
RX   PubMed=26937021; DOI=10.1124/jpet.116.232637;
RA   Foti R.S., Isoherranen N., Zelter A., Dickmann L.J., Buttrick B.R.,
RA   Diaz P., Douguet D.;
RT   "Identification of tazarotenic acid as the first xenobiotic substrate of
RT   human retinoic acid hydroxylase CYP26A1 and CYP26B1.";
RL   J. Pharmacol. Exp. Ther. 357:281-292(2016).
CC   -!- FUNCTION: A cytochrome P450 monooxygenase involved in the metabolism of
CC       retinoates (RAs), the active metabolites of vitamin A, and critical
CC       signaling molecules in animals (PubMed:10823918, PubMed:22020119). RAs
CC       exist as at least four different isomers: all-trans-RA (atRA), 9-cis-
CC       RA, 13-cis-RA, and 9,13-dicis-RA, where atRA is considered to be the
CC       biologically active isomer, although 9-cis-RA and 13-cis-RA also have
CC       activity (Probable). Catalyzes the hydroxylation of atRA primarily at
CC       C-4 and C-18, thereby contributing to the regulation of atRA
CC       homeostasis and signaling (PubMed:10823918). Hydroxylation of atRA
CC       limits its biological activity and initiates a degradative process
CC       leading to its eventual elimination (PubMed:10823918, PubMed:22020119).
CC       Involved in the convertion of atRA to all-trans-4-oxo-RA. Can oxidize
CC       all-trans-13,14-dihydroretinoate (DRA) to metabolites which could
CC       include all-trans-4-oxo-DRA, all-trans-4-hydroxy-DRA, all-trans-5,8-
CC       epoxy-DRA, and all-trans-18-hydroxy-DRA (By similarity). Shows
CC       preference for the following substrates: atRA > 9-cis-RA > 13-cis-RA
CC       (PubMed:10823918, PubMed:22020119). Plays a central role in germ cell
CC       development: acts by degrading RAs in the developing testis, preventing
CC       STRA8 expression, thereby leading to delay of meiosis. Required for the
CC       maintenance of the undifferentiated state of male germ cells during
CC       embryonic development in Sertoli cells, inducing arrest in G0 phase of
CC       the cell cycle and preventing meiotic entry. Plays a role in skeletal
CC       development, both at the level of patterning and in the ossification of
CC       bone and the establishment of some synovial joints (PubMed:22019272).
CC       Essential for postnatal survival (By similarity).
CC       {ECO:0000250|UniProtKB:Q811W2, ECO:0000269|PubMed:10823918,
CC       ECO:0000269|PubMed:22019272, ECO:0000269|PubMed:22020119,
CC       ECO:0000305|PubMed:22020119}.
CC   -!- FUNCTION: Has also a significant activity in oxidation of tazarotenic
CC       acid and may therefore metabolize that xenobiotic in vivo.
CC       {ECO:0000269|PubMed:26937021}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=all-trans-retinoate + O2 + reduced [NADPH--hemoprotein
CC         reductase] = all-trans-4-hydroxyretinoate + H(+) + H2O + oxidized
CC         [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:51984, Rhea:RHEA-
CC         COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:35291,
CC         ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:134178;
CC         Evidence={ECO:0000269|PubMed:10823918, ECO:0000269|PubMed:22020119};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:51985;
CC         Evidence={ECO:0000269|PubMed:10823918, ECO:0000269|PubMed:22020119};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=all-trans-retinoate + O2 + reduced [NADPH--hemoprotein
CC         reductase] = all-trans-18-hydroxyretinoate + H(+) + H2O + oxidized
CC         [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:55856, Rhea:RHEA-
CC         COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:35291,
CC         ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:139258;
CC         Evidence={ECO:0000250|UniProtKB:Q811W2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:55857;
CC         Evidence={ECO:0000250|UniProtKB:Q811W2};
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000250|UniProtKB:Q9Y6A2};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.01 uM for tazarotenic acid (measured in vitro by the production
CC         of tazarotenic acid-sulfoxide) {ECO:0000269|PubMed:26937021};
CC         KM=0.56 uM for tazarotenic acid (measured in vitro by the production
CC         of hydroxytazarotenic acid production) {ECO:0000269|PubMed:26937021};
CC   -!- INTERACTION:
CC       Q9NR63; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-25928065, EBI-1055254;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:O43174}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:O43174}. Microsome membrane
CC       {ECO:0000250|UniProtKB:O43174}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:O43174}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9NR63-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NR63-2; Sequence=VSP_042968;
CC       Name=3;
CC         IsoId=Q9NR63-3; Sequence=VSP_042967;
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain, particularly in the
CC       cerebellum and pons. {ECO:0000269|PubMed:10823918}.
CC   -!- INDUCTION: By retinoic acid. {ECO:0000269|PubMed:10823918}.
CC   -!- DISEASE: Radiohumeral fusions with other skeletal and craniofacial
CC       anomalies (RHFCA) [MIM:614416]: A disease characterized by craniofacial
CC       malformations, occipital encephalocele, radiohumeral fusions,
CC       oligodactyly, advanced osseous maturation, and calvarial mineralization
CC       defects. {ECO:0000269|PubMed:22019272}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAH12154.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/cyp26b1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF252297; AAF76003.1; -; mRNA.
DR   EMBL; FJ467289; ACR19332.1; -; mRNA.
DR   EMBL; AK294814; BAH11892.1; -; mRNA.
DR   EMBL; AK294933; BAH11930.1; -; mRNA.
DR   EMBL; AK295683; BAH12154.1; ALT_INIT; mRNA.
DR   EMBL; AK313433; BAG36224.1; -; mRNA.
DR   EMBL; AC007002; AAY14690.1; -; Genomic_DNA.
DR   EMBL; BC069443; AAH69443.1; -; mRNA.
DR   EMBL; BC109205; AAI09206.1; -; mRNA.
DR   CCDS; CCDS1919.1; -. [Q9NR63-1]
DR   CCDS; CCDS62934.1; -. [Q9NR63-2]
DR   RefSeq; NP_001264671.1; NM_001277742.1. [Q9NR63-2]
DR   RefSeq; NP_063938.1; NM_019885.3. [Q9NR63-1]
DR   AlphaFoldDB; Q9NR63; -.
DR   SMR; Q9NR63; -.
DR   BioGRID; 121153; 35.
DR   IntAct; Q9NR63; 1.
DR   STRING; 9606.ENSP00000001146; -.
DR   BindingDB; Q9NR63; -.
DR   ChEMBL; CHEMBL3713687; -.
DR   DrugBank; DB00755; Tretinoin.
DR   SwissLipids; SLP:000001876; -.
DR   iPTMnet; Q9NR63; -.
DR   PhosphoSitePlus; Q9NR63; -.
DR   BioMuta; CYP26B1; -.
DR   DMDM; 20137526; -.
DR   MassIVE; Q9NR63; -.
DR   MaxQB; Q9NR63; -.
DR   PaxDb; Q9NR63; -.
DR   PeptideAtlas; Q9NR63; -.
DR   ProteomicsDB; 82286; -. [Q9NR63-1]
DR   ProteomicsDB; 82287; -. [Q9NR63-2]
DR   ProteomicsDB; 82288; -. [Q9NR63-3]
DR   Antibodypedia; 2113; 314 antibodies from 34 providers.
DR   DNASU; 56603; -.
DR   Ensembl; ENST00000001146.7; ENSP00000001146.2; ENSG00000003137.9. [Q9NR63-1]
DR   Ensembl; ENST00000546307.5; ENSP00000443304.1; ENSG00000003137.9. [Q9NR63-2]
DR   GeneID; 56603; -.
DR   KEGG; hsa:56603; -.
DR   MANE-Select; ENST00000001146.7; ENSP00000001146.2; NM_019885.4; NP_063938.1.
DR   UCSC; uc002sih.3; human. [Q9NR63-1]
DR   AGR; HGNC:20581; -.
DR   CTD; 56603; -.
DR   DisGeNET; 56603; -.
DR   GeneCards; CYP26B1; -.
DR   HGNC; HGNC:20581; CYP26B1.
DR   HPA; ENSG00000003137; Tissue enhanced (brain, skin).
DR   MalaCards; CYP26B1; -.
DR   MIM; 605207; gene.
DR   MIM; 614416; phenotype.
DR   neXtProt; NX_Q9NR63; -.
DR   OpenTargets; ENSG00000003137; -.
DR   Orphanet; 293925; Lethal occipital encephalocele-skeletal dysplasia syndrome.
DR   PharmGKB; PA134879191; -.
DR   VEuPathDB; HostDB:ENSG00000003137; -.
DR   eggNOG; KOG0157; Eukaryota.
DR   GeneTree; ENSGT00800000124060; -.
DR   InParanoid; Q9NR63; -.
DR   OMA; AHMCLGL; -.
DR   OrthoDB; 758626at2759; -.
DR   PhylomeDB; Q9NR63; -.
DR   TreeFam; TF105093; -.
DR   PathwayCommons; Q9NR63; -.
DR   Reactome; R-HSA-211916; Vitamins.
DR   Reactome; R-HSA-5365859; RA biosynthesis pathway.
DR   Reactome; R-HSA-5579015; Defective CYP26B1 causes RHFCA.
DR   SABIO-RK; Q9NR63; -.
DR   SignaLink; Q9NR63; -.
DR   BioGRID-ORCS; 56603; 17 hits in 1164 CRISPR screens.
DR   ChiTaRS; CYP26B1; human.
DR   GeneWiki; CYP26B1; -.
DR   GenomeRNAi; 56603; -.
DR   Pharos; Q9NR63; Tchem.
DR   PRO; PR:Q9NR63; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q9NR63; protein.
DR   Bgee; ENSG00000003137; Expressed in pons and 164 other tissues.
DR   ExpressionAtlas; Q9NR63; baseline and differential.
DR   Genevisible; Q9NR63; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0020037; F:heme binding; NAS:BHF-UCL.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0004497; F:monooxygenase activity; IBA:GO_Central.
DR   GO; GO:0016709; F:oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen; IDA:UniProtKB.
DR   GO; GO:0008401; F:retinoic acid 4-hydroxylase activity; IDA:BHF-UCL.
DR   GO; GO:0001972; F:retinoic acid binding; IDA:BHF-UCL.
DR   GO; GO:0060349; P:bone morphogenesis; IMP:UniProtKB.
DR   GO; GO:0001709; P:cell fate determination; ISS:BHF-UCL.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0070268; P:cornification; IEA:Ensembl.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0061436; P:establishment of skin barrier; IEA:Ensembl.
DR   GO; GO:0001768; P:establishment of T cell polarity; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0001822; P:kidney development; IEA:Ensembl.
DR   GO; GO:0007140; P:male meiotic nuclear division; ISS:BHF-UCL.
DR   GO; GO:0048387; P:negative regulation of retinoic acid receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:2001037; P:positive regulation of tongue muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0009954; P:proximal/distal pattern formation; ISS:BHF-UCL.
DR   GO; GO:0045580; P:regulation of T cell differentiation; IEA:Ensembl.
DR   GO; GO:0033189; P:response to vitamin A; IEA:Ensembl.
DR   GO; GO:0034653; P:retinoic acid catabolic process; IDA:BHF-UCL.
DR   GO; GO:0042573; P:retinoic acid metabolic process; IDA:UniProtKB.
DR   GO; GO:0048384; P:retinoic acid receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; ISS:BHF-UCL.
DR   GO; GO:0016125; P:sterol metabolic process; IBA:GO_Central.
DR   GO; GO:0043587; P:tongue morphogenesis; IEA:Ensembl.
DR   GO; GO:0006766; P:vitamin metabolic process; TAS:Reactome.
DR   GO; GO:0006805; P:xenobiotic metabolic process; IDA:UniProtKB.
DR   CDD; cd20637; CYP26B1; 1.
DR   Gene3D; 1.10.630.10; Cytochrome P450; 1.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002403; Cyt_P450_E_grp-IV.
DR   InterPro; IPR036396; Cyt_P450_sf.
DR   PANTHER; PTHR24286; CYTOCHROME P450 26; 1.
DR   PANTHER; PTHR24286:SF177; CYTOCHROME P450 26B1; 1.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00465; EP450IV.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; Cytochrome P450; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Craniosynostosis; Disease variant;
KW   Endoplasmic reticulum; Heme; Iron; Lipid metabolism; Membrane;
KW   Metal-binding; Microsome; Monooxygenase; Oxidoreductase;
KW   Reference proteome.
FT   CHAIN           1..512
FT                   /note="Cytochrome P450 26B1"
FT                   /id="PRO_0000051985"
FT   BINDING         441
FT                   /ligand="heme"
FT                   /ligand_id="ChEBI:CHEBI:30413"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..67
FT                   /note="MLFEGLDLVSALATLAACLVSVTLLLAVSQQLWQLRWAATRDKSCKLPIPKG
FT                   SMGFPLIGETGHWLL -> MKNKTCVLVCVSVFGGERGQVTVPRVGVRRPSLAGPLQKC
FT                   TLRETRVWLP (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042967"
FT   VAR_SEQ         69..143
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.2"
FT                   /id="VSP_042968"
FT   VARIANT         64
FT                   /note="H -> R"
FT                   /evidence="ECO:0000269|PubMed:26937021"
FT                   /id="VAR_075982"
FT   VARIANT         146
FT                   /note="S -> P (in RHFCA; dbSNP:rs281875232)"
FT                   /evidence="ECO:0000269|PubMed:22019272"
FT                   /id="VAR_067923"
FT   VARIANT         181
FT                   /note="V -> M (in dbSNP:rs142999899)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038722"
FT   VARIANT         185
FT                   /note="A -> V (in dbSNP:rs765423228)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038723"
FT   VARIANT         191
FT                   /note="R -> H (in dbSNP:rs76025186)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038724"
FT   VARIANT         227
FT                   /note="D -> N (in dbSNP:rs143738797)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038725"
FT   VARIANT         264
FT                   /note="L -> S (in dbSNP:rs2241057)"
FT                   /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.2,
FT                   ECO:0000269|Ref.4"
FT                   /id="VAR_024383"
FT   VARIANT         363
FT                   /note="R -> L (in RHFCA; dbSNP:rs281875231)"
FT                   /evidence="ECO:0000269|PubMed:22019272"
FT                   /id="VAR_067924"
FT   VARIANT         380
FT                   /note="E -> K (in dbSNP:rs2286965)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038726"
FT   VARIANT         420
FT                   /note="A -> G (in dbSNP:rs7568553)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038727"
FT   VARIANT         473
FT                   /note="R -> C (in dbSNP:rs61751056)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038728"
FT   VARIANT         479
FT                   /note="V -> I (in dbSNP:rs148075682)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038729"
FT   CONFLICT        265
FT                   /note="D -> G (in Ref. 3; BAH11930)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   512 AA;  57513 MW;  A06D1D9944E6726F CRC64;
     MLFEGLDLVS ALATLAACLV SVTLLLAVSQ QLWQLRWAAT RDKSCKLPIP KGSMGFPLIG
     ETGHWLLQGS GFQSSRREKY GNVFKTHLLG RPLIRVTGAE NVRKILMGEH HLVSTEWPRS
     TRMLLGPNTV SNSIGDIHRN KRKVFSKIFS HEALESYLPK IQLVIQDTLR AWSSHPEAIN
     VYQEAQKLTF RMAIRVLLGF SIPEEDLGHL FEVYQQFVDN VFSLPVDLPF SGYRRGIQAR
     QILQKGLEKA IREKLQCTQG KDYLDALDLL IESSKEHGKE MTMQELKDGT LELIFAAYAT
     TASASTSLIM QLLKHPTVLE KLRDELRAHG ILHSGGCPCE GTLRLDTLSG LRYLDCVIKE
     VMRLFTPISG GYRTVLQTFE LDGFQIPKGW SVMYSIRDTH DTAPVFKDVN VFDPDRFSQA
     RSEDKDGRFH YLPFGGGVRT CLGKHLAKLF LKVLAVELAS TSRFELATRT FPRITLVPVL
     HPVDGLSVKF FGLDSNQNEI LPETEAMLSA TV
//
